VISIONARY

venture capital fund with a unique information advantage approach
and strategy to connect capital and insight with the most promising startups
Learn More - Creating Value with Better Insight

— About Us

WHAT WE DO

VISIONARY VENTURES

We believe that better information leads to better investments with exceptional returns.

We gain that information through partnerships with KOL’s, industry experts, and strategic acquirers. By building a team of specialists, professionals, and industry leaders at the forefront of the process, we are tapping into a unique advantage to our venture investments.

One of our key focus areas aside from achieving exceptional returns is investing in companies that address unmet or underserved markets. When companies focus on a larger societal impact, we are funding true change. With a team of professionals impacting these decisions, we can make the most informed decisions about how we vet these companies and gauge their potential.

We’re looking for visionary and proven entrepreneurs who are turning exciting ideas into market-leading businesses. We are a focused venture capital fund from series A to commercialization. Our target investments range from $5M to $15M.

– What are KOL’s?

KOL’s or Key Opinion Leaders are made up of the best and brightest in a common field or industry. Together they provide years of experience and a vast knowledge base that allows this group to accurately source, vet, and advocate the best deals. Through a peer review system, they can provide expert guidance and insight to fund management.

— About Us

WHAT WE DO

VISIONARY VENTURES

We believe that better information leads to better investments with exceptional returns.

We gain that information through partnerships with KOL’s, industry experts, and strategic acquirers. By building a team of specialists, professionals, and industry leaders at the forefront of the process, we are tapping into a unique advantage to our venture investments.

One of our key focus areas aside from achieving exceptional returns is investing in companies that address unmet or underserved markets. When companies focus on a larger societal impact, we are funding true change. With a team of professionals impacting these decisions, we can make the most informed decisions about how we vet these companies and gauge their potential.

We’re looking for visionary and proven entrepreneurs who are turning exciting ideas into market-leading businesses. We are a focused venture capital fund from series A to commercialization. Our target investments range from $5M to $15M.

– What are KOL’s?

KOL’s or Key Opinion Leaders are made up of the best and brightest in a common field or industry. Together they provide years of experience and a vast knowledge base that allows this group to accurately source, vet, and advocate the best deals. Through a peer review system, they can provide expert guidance and insight to fund management.

— About Us

WHAT WE DO

VISIONARY VENTURES

We believe that better information leads to better investments with exceptional returns.

We gain that information through partnerships with KOL’s, industry experts, and strategic acquirers. By building a team of specialists, professionals, and industry leaders at the forefront of the process, we are tapping into a unique advantage to our venture investments.

One of our key focus areas aside from achieving exceptional returns is investing in companies that address unmet or underserved markets. When companies focus on a larger societal impact, we are funding true change. With a team of professionals impacting these decisions, we can make the most informed decisions about how we vet these companies and gauge their potential.

We’re looking for visionary and proven entrepreneurs who are turning exciting ideas into market-leading businesses. We are a focused venture capital fund from series A to commercialization. Our target investments range from $5M to $15M.

– What are KOL’s?

KOL’s or Key Opinion Leaders are made up of the best and brightest in a common field or industry. Together they provide years of experience and a vast knowledge base that allows this group to accurately source, vet, and advocate the best deals. Through a peer review system, they can provide expert guidance and insight to fund management.

Emerging Company Product Intellectual Property Proven Team Big Market with
major improvement/
transformational tech
Capital KOL Clinical Value
Assessment
Strategic Direction Implementation
Resources
Partnering with
strategics
Strategic Purchase de-risked
assets ready for
market
Strong partnering
relationship with
Visionary
Global scale and
resources
Serves more
patients quickly

August 6, 2025 TARSUS REPORTS Q2 2025 FINANCIAL RESULTS Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Read more Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration July 28, 2025 Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. July 22, 2025 June 24, 2025 March 26, 2025 ALCON ACQUIRES MAJORITY INTEREST IN AURION BIOTECH, INC. TO ADVANCE INNOVATIVE CELL THERAPY FOR CORNEAL ENDOTHELIAL DISEASE View More Read More SANTEN LAUNCHES RYJUNEA® IN GERMANY FOR
THE TREATMENT OF PEDIATRIC MYOPIA
PELAGE ANNOUNCES POSITIVE PHASE 2A
CLINICAL TRIAL RESULTS IN REGENERATIVE
HAIR LOSS THERAPY
LATEST NEWS Updates Read More Read More Read More

NEWSLETTER

Subscribe your e-mail to get the news

  • This field is for validation purposes and should be left unchanged.